Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma ApplicationsGlobeNewsWire • 09/10/24
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome TechnologyGlobeNewsWire • 09/03/24
Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™GlobeNewsWire • 08/28/24
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome SerumGlobeNewsWire • 08/26/24
Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health ApplicationsGlobeNewsWire • 08/19/24
Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/14/24
Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhDGlobeNewsWire • 07/30/24
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 ConferenceGlobeNewsWire • 05/22/24
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of ObesityGlobeNewsWire • 05/02/24
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome SkincareGlobeNewsWire • 05/01/24
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity TreatmentsGlobeNewsWire • 05/01/24
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue CommitmentsGlobeNewsWire • 04/29/24
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 MonthsGlobeNewsWire • 04/22/24
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial ResultsGlobeNewsWire • 03/29/24
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical MarketGlobeNewsWire • 03/18/24
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark OfficeGlobeNewsWire • 01/24/24
Top 4 Defensive Stocks That Could Lead To Your Biggest Gains In January - AgriFORCE Growing Systems (NASDAQ:AGRI), Archer-Daniels Midland (NYSE:ADM)Benzinga • 01/23/24
ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global ReachGlobeNewsWire • 01/17/24
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing TechnologyGlobeNewsWire • 01/16/24